Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.43 |
| ▸ | JAK2 | O60674 | 4/20 | 0.42 |
| ▸ | JAK1 | P23458 | 4/20 | 0.42 |
| ▸ | STS | P08842 | 3/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6963424 | 0.90 | MEN1 (0.46) | CYP3A4CYP3A5MEN1KMT2AJAK2 | |
| SCHEMBL7527349 | 0.89 | GPR119 (0.44) | GPR119JAK2JAK1 | |
| SCHEMBL29995192 | 0.89 | GPR119 (0.44) | GPR119JAK2JAK1 | |
| SCHEMBL2779561 | 0.88 | GPR119 (0.43) | KMT2AGPR119JAK2JAK1 | |
| SCHEMBL28597678 | 0.87 | USP30 (0.46) | USP30GPR119JAK2JAK1 | |
| SCHEMBL31415651 | 0.86 | MEN1 (0.44) | CYP3A4CYP3A5MEN1KMT2AGPR119 | |
| SCHEMBL2468693 | 0.85 | GPR119 (0.43) | GPR119JAK2JAK1 | |
| SCHEMBL12877871 | 0.84 | PDK2 (0.44) | MEN1KMT2AGPR119JAK2JAK1 | |
| SCHEMBL2474368 | 0.83 | KIT (0.44) | MEN1KMT2AUSP30JAK2JAK1 | |
| SCHEMBL651457 | 0.82 | OPRM1 (0.56) | MEN1KMT2AJAK2JAK1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370423-A1 | METHOD FOR PREPARING A SPIROINDOLINE AND A PRECURSOR THEREOF | Glaxo Group Limited (GB) | 2011-10-05 | — | — | EP | claimed |
| US-20110230660-A1 | METHOD FOR PREPARING A SPIROINDOLINE AND A PRECURSOR THEREOF | Method for Preparing a Spiroindoline | 2011-09-22 | — | — | US | claimed |
| WO-2010065704-A1 | METHOD FOR PREPARING A SPIROINDOLINE AND A PRECURSOR THEREOF | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | WO | claimed |
| US-8431590-B2 | Spiroindolines as modulators of chemokine receptors | GLAXO GROUP LIMITED (GB) | 2013-04-30 | — | — | US | disclosed |
| US-8431590-B2 | Spiroindolines as modulators of chemokine receptors | GLAXO GROUP LIMITED (GB) | 2013-04-30 | — | — | US | disclosed |
| US-8431590-B2 | Spiroindolines as modulators of chemokine receptors | GLAXO GROUP LIMITED (GB) | 2013-04-30 | — | — | US | disclosed |
| EP-2370423-A1 | METHOD FOR PREPARING A SPIROINDOLINE AND A PRECURSOR THEREOF | Glaxo Group Limited (GB) | 2011-10-05 | — | — | EP | disclosed |
| US-20110230660-A1 | METHOD FOR PREPARING A SPIROINDOLINE AND A PRECURSOR THEREOF | Method for Preparing a Spiroindoline | 2011-09-22 | — | — | US | disclosed |
| US-20110230660-A1 | METHOD FOR PREPARING A SPIROINDOLINE AND A PRECURSOR THEREOF | Method for Preparing a Spiroindoline | 2011-09-22 | — | — | US | disclosed |
| US-20110230660-A1 | METHOD FOR PREPARING A SPIROINDOLINE AND A PRECURSOR THEREOF | Method for Preparing a Spiroindoline | 2011-09-22 | — | — | US | disclosed |
| US-20110034499-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2011-02-10 | — | — | US | disclosed |
| US-7723350-B2 | Spiroindolines as modulators of chemokine receptors | GLAXO GROUP LIMITED (GB) | 2010-05-25 | — | — | US | disclosed |
| EP-2166848-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | Glaxo Group Limited (GB) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009061881-A1 | SPIRODIHYDROBENZOFURANS AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009061881-A1 | SPIRODIHYDROBENZOFURANS AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-05-14 | — | — | WO | disclosed |
| US-20080318990-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| US-20080318990-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| US-20080318990-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| WO-2008157741-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157741-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318990-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CCR10, CXCR2 | CYP3A4 2351/4885CYP3A5 1089/4885MEN1 1818/4885 |
| US-20110034499-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CCR10, CXCR2 | CYP3A4 2351/4885CYP3A5 1089/4885MEN1 1818/4885 |
| US-20110230660-A1 | METHOD FOR PREPARING A SPIROINDOLINE AND A PRECURSOR THEREOF | CCR2, CXCR4, CXCR2 | CYP3A4 655/4885CYP3A5 1020/4885MEN1 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.